Comparative Pharmacology
Head-to-head clinical analysis: TACE versus THEELIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TACE versus THEELIN.
TACE vs THEELIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
TACE (Transcatheter Arterial Chemoembolization) is not a drug but a procedure combining intra-arterial chemotherapy and embolization. Chemotherapeutic agents (e.g., doxorubicin, cisplatin) are delivered directly to tumor-feeding arteries, inducing cytotoxicity, while embolic agents (e.g., lipiodol, microspheres) occlude blood flow, causing ischemia and enhancing drug retention.
Estrogen receptor agonist; binds to estrogen receptors (ERα and ERβ), modulating gene transcription and promoting estrogenic effects.
Transarterial chemoembolization (TACE) with doxorubicin: 50-75 mg/m² or up to 150 mg total dose, administered via hepatic artery injection, repeated every 4-6 weeks as tolerated.
Intramuscular: 0.22 to 1.1 mg (220 to 1100 mcg) once weekly for menopausal symptoms; 0.5 to 2 mg (500 to 2000 mcg) once weekly for prostatic carcinoma.
None Documented
None Documented
Variable depending on the drug; for doxorubicin, terminal half-life is 24-36 hours, clinically relevant for systemic toxicity.
Terminal elimination half-life: 13–19 hours (mean 16 h); clinical context: supports once-daily dosing for estrogen replacement.
TACE is not a specific drug but a procedure (transarterial chemoembolization). The chemotherapeutic agents used (e.g., doxorubicin, cisplatin, mitomycin C) are typically eliminated via hepatic metabolism and biliary excretion, with renal excretion as a minor route (<10% for doxorubicin).
Renal: ~50% as glucuronide and sulfate conjugates; fecal: ~30% via enterohepatic recirculation; biliary: ~20%.
Category C
Category C
Estrogen
Estrogen